No Data
Investors Push UniQure (NASDAQ:QURE) 7.1% Lower This Week, Company's Increasing Losses Might Be to Blame
UniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years
UniQure Completes First Cohort Enrollment in Gene Therapy Trial for Fabry Disease, Safety Review Clears Path for Next Phase
UniQure Announces Favorable Recommendation From Independent Data Monitoring Committee for Its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS
H.C. Wainwright Maintains UniQure NV(QURE.US) With Buy Rating, Raises Target Price to $70
UniQure Analyst Ratings